Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
CAMBRIDGE, Mass., Sept. 26, 2016 -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the annual Cell & Gene Meeting on the Mesa at the Estancia La Jolla Hotel & Spa in La Jolla, CA on Wednesday, October 5, 2016 at 5:45pm Pacific time.
Organized by ARM and the Sanford Consortium for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference organized specifically for the cell and gene therapy and regenerative medicine sector.
The presentation will be webcast live at: http://www.meetingonthemesa.com/webcast/ and will also be published on ARM’s website shortly after the event.
About Vericel Corporation
Vericel develops, manufactures, and markets autologous expanded cell therapies for the treatment of patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Carticel® (autologous cultured chondrocytes) is an autologous chondrocyte implant for the treatment of cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing two additional cell products. MACI® is a third generation autologous chondrocyte implant intended to treat cartilage defects in the knee. Ixmyelocel‑T is an autologous multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). For more information, please visit the company's website at www.vcel.com.
Epicel®, Carticel® and MACI® are registered trademarks of Vericel Corporation. ©2016 Vericel Corporation. All rights reserved.
CONTACT: Chad Rubin The Trout Group [email protected] (646) 378-2947 or Lee Stern The Trout Group [email protected] (646) 378-2922
